The role of the primitive marker CD133 in CD34 ‐negative acute myeloid leukemia for the detection of leukemia stem cells
Cytometry Part B: Clinical Cytometry · 2025
DOI: 10.1002/cyto.b.22201 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cytometry Part B: Clinical Cytometry, 2025. Verfasst von Tom Reuvekamp und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Amsterdam UMC location Vrije Universiteit Amsterdam, Amsterdam, The Netherlands. Hauptthemen laut MEDLINE: AC133 Antigen, Leukemia, Myeloid, Acute, Neoplastic Stem Cells, Antigens, CD34. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
The most important reason for dismal outcomes in acute myeloid leukemia (AML) is the development of relapse. Leukemia stem cells (LSCs) are hypothesized to initiate relapse, and high CD34+CD38− LSC load is associated with poor prognosis. In 10% of AML patients, CD34 is not or is low expressed on the leukemic cells (
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hematology, Amsterdam UMC location Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.
- Cancer Center Amsterdam, Imaging and Biomarkers, Amsterdam, The Netherlands.
- Department of Hematology, Amsterdam UMC location Universiteit van Amsterdam, Amsterdam, The Netherlands.
- Department of Hematology, Erasmus MC Cancer Institute and University Medical Center Rotterdam, Rotterdam, The Netherlands.
- Department of Radiology and Nuclear Medicine, Amsterdam UMC location Universiteit van Amsterdam, Amsterdam, The Netherlands.
- HOVON Foundation, Rotterdam, The Netherlands.
ORCID-Profile: Tom Reuvekamp, Costa Bachas, Jacqueline Cloos
Zitieren
APA
Reuvekamp, T., Janssen, L. L. G., Ngai, L. L., Carbaat-Ham, J., den Hartog, D., Scholten, W. J., Kelder, A., Hanekamp, D., Wensink, E., van Gils, N., Gradowska, P., Löwenberg, B., Ossenkoppele, G. J., van de Loosdrecht, A. A., Westers, T. M., Smit, L., Bachas, C., & Cloos, J. (2025). The role of the primitive marker CD133 in CD34 ‐negative acute myeloid leukemia for the detection of leukemia stem cells. Cytometry Part B: Clinical Cytometry. https://doi.org/10.1002/cyto.b.22201
Vancouver
Reuvekamp T, Janssen LLG, Ngai LL, Carbaat-Ham J, den Hartog D, Scholten WJ, et al. The role of the primitive marker CD133 in CD34 ‐negative acute myeloid leukemia for the detection of leukemia stem cells. Cytometry Part B: Clinical Cytometry. 2025. doi:10.1002/cyto.b.22201
BibTeX
@article{Reuvekamp2025,
author = {Reuvekamp, Tom and Janssen, Luca L G and Ngai, Lok Lam and Carbaat-Ham, Jannemieke and den Hartog, Daphne and Scholten, Willemijn J and Kelder, Angèle and Hanekamp, Diana and Wensink, Eliza and van Gils, Noortje and Gradowska, Patrycja and Löwenberg, Bob and Ossenkoppele, Gert J and van de Loosdrecht, Arjan A and Westers, Theresia M and Smit, Linda and Bachas, Costa and Cloos, Jacqueline},
title = {The role of the primitive marker CD133 in CD34 ‐negative acute myeloid leukemia for the detection of leukemia stem cells},
journal = {Cytometry Part B: Clinical Cytometry},
year = {2025},
doi = {10.1002/cyto.b.22201}
}
EUVIMED